公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2018 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer | Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG ; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. | Journal of Clinical Oncology | 245 | 211 | |
2018 | Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer | Wu Y.-L; CHIH-HSIN YANG ; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. | Journal of Clinical Oncology | 240 | 183 | |
2017 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit E.F; Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG ; Zhou C; Vokes E. | Journal of Thoracic Oncology | 184 | 168 | |
2017 | Scientific Advances in Thoracic Oncology 2016 | Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG ; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. | Journal of Thoracic Oncology | 42 | 31 | |
2019 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer | Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG ; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. | Lung Cancer | 26 | 26 | |
2008 | Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles | Lee T.-H; Liu C.-H; Huang C.-C; Wu Y.-L; Shih Y.-T; HONG-NERNG HO ; YU-SHIH YANG ; Lee M.-S. | Human Reproduction | 242 | 189 | |
2013 | Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study | Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Chu D.-T; Rukazenkov Y. | Lung Cancer | 41 | 39 |